One receptor can protect antibodies from degradation, extend their half-life and become a drug target itself. Explore the ...

The alternative text for this image may have been generated using AI. IgG is the predominant antibody isotype found in the female genital tract and serves as an important defence mechanism against ...

NEW YORK--(BUSINESS WIRE)--Syntimmune, Inc., a clinical-stage biotechnology company focused on breakthrough therapies based on FcRn biology, today announced robust clinical data from the Phase 1a ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab ...

Immunovant’s decision to prioritize a next-gen FcRn antibody over phase 3 myasthenia gravis (MG) prospect batoclimab means Vyvgart’s crown remains secure for the time being, analysts have concluded.

Fc receptor based affinity chromatography is a new emerging field of Fc functionality analytics. FcRn affinity columns separate antibody species that differ in their affinity to FcRn using conditions ...

In the quest to advance therapeutic development, the creation of transgenic mouse models expressing human proteins has become increasingly prevalent. These models have a unique ability to address gaps ...

Clinicians in Europe may soon gain access to a first-in-class neonatal Fc receptor (FcRn) inhibitor for generalized myasthenia gravis (gMG). Imaavy (nipocalimab; Janssen-Cilag International) received ...

Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering ...

SYNT001 is a first-in-class monoclonal antibody that blocks FcRn-IgG interactions and is being developed for the treatment of a broad variety of autoimmune diseases that are dependent upon IgG. An ...